Top

BMC Psychiatry

Published in:

Open Access 01-12-2020 | Schizophrenia | Research article

Peripheral non-enzymatic antioxidants in patients with schizophrenia: a case-control study

Authors: Zhe Lu, Tianyang Wen, Yingtan Wang, Weijing Kan, Guanglei Xun

Published in: BMC Psychiatry | Issue 1/2020

Abstract

Background

Recent studies show that oxidative stress is associated with the pathogenesis of schizophrenia. There are two major types of antioxidant systems in vivo, namely enzymatic antioxidants and non-enzymatic antioxidants. This study investigated differences of non-enzymatic antioxidants between schizophrenia patients and healthy controls.

Methods

Peripheral UA, ALB, and TBIL of 107 schizophrenic patients in the acute stage and 101 in the remission stage were measured respectively, so were 273 healthy controls.

Results

The levels of UA (P = 0.020) and TBIL (P < 0.001) of schizophrenic patients in the acute stage were higher than those of healthy controls, while the level of ALB (P < 0.001) was lower. Similar results were detected form schizophrenic patients in the remission stage. Schizophrenic patients in the acute stage were divided into antipsychotics-use subgroup (n = 56) and antipsychotics-naïve/free subgroup (n = 51). The level of UA (P = 0.001) in the antipsychotics-use subgroup was higher than that in the antipsychotics-naïve/free subgroup, while the level of TBIL (P = 0.002) was lower than that in the antipsychotics-naïve/free subgroup. Seventy-seven schizophrenic patients in the acute stage were followed up, and there was no significant difference in the level of UA before and after treatment, but levels of ALB (P < 0.001) and TBIL (P < 0.001) decreased significantly after the treatment.

Conclusion

This study demonstrated that the dysfunction of the peripheral non-enzymatic anti-oxidation system might be involved in the pathogenesis of schizophrenia.

Lohr JB. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiatry. 1991;48(12):1097–106. https://doi.org/10.1001/archpsyc.1991.01810360061009.CrossRefPubMed

Lai CY, Scarr E, Udawela M, Everall I, Chen WJ, Dean B. Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics. World J Psychiatry. 2016;6(1):102–17. https://doi.org/10.5498/wjp.v6.i1.102.CrossRefPubMedPubMedCentral

Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84. https://doi.org/10.1016/j.biocel.2006.07.001.CrossRef

Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem. 2015;97:55–74. https://doi.org/10.1016/j.ejmech.2015.04.040.CrossRefPubMed

Parikh V, Khan MM, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res. 2003;37(1):43–51. https://doi.org/10.1016/s0022-3956(02)00048-1.CrossRefPubMed

Poljsak B, Suput D, Milisav I. Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid Med Cell Longev. 2013;2013:956792. https://doi.org/10.1155/2013/956792.CrossRefPubMedPubMedCentral

Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Rad Biol Med. 2001;31(11):1287–312. https://doi.org/10.1016/s0891-5849(01)00724-9.CrossRefPubMed

Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antiox Redox Signal. 2011;15(7):2011–35. https://doi.org/10.1089/ars.2010.3603.CrossRef

Moniczewski A, Gawlik M, Smaga I, Niedzielska E, Krzek J, Przegalinski E, et al. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 1. Chemical aspects and biological sources of oxidative stress in the brain. Pharm Rep. 2015;67(3):560–8. https://doi.org/10.1016/j.pharep.2014.12.014.CrossRef

10.

Sarandol A, Sarandol E, Acikgoz HE, Eker SS, Akkaya C, Dirican M. First-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment. Psychiatry Clin Neurosci. 2015;69(11):699–1. https://doi.org/10.1111/pcn.12333.CrossRefPubMed

11.

Pandya CD, Howell KR, Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:214–23. https://doi.org/10.1016/j.pnpbp.2012.10.017.CrossRefPubMed

12.

Bulbul F, Virit O, Alpak G, Unal A, Bulut M, Kaya MC, et al. Are oxidative stress markers useful to distinguish schizoaffective disorder from schizophrenia and bipolar disorder? Acta neuropsychiatrica. 2014;26(2):120–4. https://doi.org/10.1017/neu.2013.44.CrossRefPubMed

13.

Koga M, Serritella AV, Sawa A, Sedlak TW. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr Res. 2016;176(1):52–71. https://doi.org/10.1016/j.schres.2015.06.022.CrossRefPubMed

14.

Yao JK, Leonard S, Reddy RD. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull. 2004;30(4):923–34. https://doi.org/10.1093/oxfordjournals.schbul.a007142.CrossRefPubMed

15.

Radonjic NV, Knezevic ID, Vilimanovich U, Kravic-Stevovic T, Marina LV, Nikolic T, et al. Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Neuropharmacology. 2010;58(4–5):739–45. https://doi.org/10.1016/j.neuropharm.2009.12.009.CrossRefPubMed

16.

Droge W. The plasma redox state and ageing. Ageing Res Rev. 2002;1(2):257–78. https://doi.org/10.1016/s1568-1637(01)00008-3.CrossRefPubMed

17.

Papas AM. Determinants of antioxidant status in humans. Lipids. 1996;31(Suppl):S77–82. https://doi.org/10.1007/bf02637055.CrossRefPubMed

18.

Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann New York Acad Sci. 1993;686:12–27; discussion −8. https://doi.org/10.1111/j.1749-6632.1993.tb39148.x.CrossRef

19.

Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, Kuschinsky K. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn-Schmiedeberg's Arch Pharmacol. 1998;358(3):351–9. https://doi.org/10.1007/pl00005264.CrossRef

20.

Al-Chalabi BM, Thanoon IA, Ahmed FA. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology. 2009;59(1):8–11. https://doi.org/10.1159/000202823.CrossRefPubMed

21.

Eftekhari A, Azarmi Y, Parvizpur A, Eghbal MA. Involvement of oxidative stress and mitochondrial/lysosomal cross-talk in olanzapine cytotoxicity in freshly isolated rat hepatocytes. Xenobiotica. 2016;46(4):369–78. https://doi.org/10.3109/00498254.2015.1078522.CrossRefPubMed

22.

Brinholi FF, Farias CC, Bonifacio KL, Higachi L, Casagrande R, Moreira EG, et al. Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models. Biomed Pharmacother. 2016;81:411–5. https://doi.org/10.1016/j.biopha.2016.02.047.CrossRefPubMed

23.

Dietrich-Muszalska A, Kopka J, Kwiatkowska A. The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison. Neurochem Res. 2013;38(7):1490–5. https://doi.org/10.1007/s11064-013-1050-z.CrossRefPubMed

24.

Singh OP, Chakraborty I, Dasgupta A, Datta S. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J Psychiatry. 2008;50(3):171–6. https://doi.org/10.4103/0019-5545.43627.CrossRefPubMedPubMedCentral

25.

Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003;62(3):205–12. https://doi.org/10.1016/s0920-9964(02)00407-3.CrossRefPubMed

26.

Widschwendter CG, Rettenbacher MA, Kemmler G, Edlinger M, Baumgartner S, Fleischhacker WW, et al. Bilirubin concentration correlates with positive symptoms in patients with schizophrenia. J Clin Psychiatry. 2016;77(4):512–6. https://doi.org/10.4088/JCP.14m09642.CrossRefPubMed

27.

Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–9. https://doi.org/10.1176/appi.ajp.162.3.441.CrossRefPubMed

28.

Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet. 1994;344(8924):721–4. https://doi.org/10.1016/s0140-6736(94)92211-x.CrossRefPubMed

29.

Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (London). 1993;84(4):407–412.https://doi.org/10.1042/cs0840407.

30.

Maxwell SR, Dietrich T, Chapple IL. Prediction of serum total antioxidant activity from the concentration of individual serum antioxidants. Clin Chim Acta. 2006;372(1–2):188–94. https://doi.org/10.1016/j.cca.2006.04.015.CrossRefPubMed

31.

Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):608–19. https://doi.org/10.1080/15257770802138558.CrossRefPubMedPubMedCentral

32.

Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, et al. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia. PLoS One. 2010;5(3):e9508. https://doi.org/10.1371/journal.pone.0009508.CrossRefPubMedPubMedCentral

33.

Chen S, Xia HS, Zhu F, Yin GZ, Qian ZK, Jiang CX, et al. Association between decreased serum albumin levels and depressive symptoms in patients with schizophrenia in a Chinese Han population: A pilot study. Psychiatry Res. 2018;270:438–42. https://doi.org/10.1016/j.psychres.2018.10.012.CrossRefPubMed

34.

Solberg DK, Refsum H, Andreassen OA, Bentsen H. A five-year follow-up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia. Acta Neuropsychiatr. 2019;31(4):202–12. https://doi.org/10.1017/neu.2019.14.CrossRefPubMed

35.

Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci. 1987;84(16):5918–22. https://doi.org/10.1073/pnas.84.16.5918.CrossRefPubMed

36.

Muller N, Schiller P, Ackenheil M. Coincidence of schizophrenia and hyperbilirubinemia. Pharmacopsychiatry. 1991;24(6):225–8. https://doi.org/10.1055/s-2007-1014472.CrossRefPubMed

37.

Dani C, Martelli E, Bertini G, Pezzati M, Filippi L, Rossetti M, et al. Plasma bilirubin level and oxidative stress in preterm infants. Arch Dis Childhood Fetal Neonatal edit. 2003;88(2):F119–23. https://doi.org/10.1136/fn.88.2.f119.CrossRef

38.

Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, Lee CU. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology. 2004;50(1):54–6. https://doi.org/10.1159/000077942.CrossRefPubMed

39.

Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull. 2004;30(4):901–11. https://doi.org/10.1093/oxfordjournals.schbul.a007140.CrossRefPubMed

40.

Vitek L, Novotna M, Lenicek M, Novotny L, Eberova J, Petrasek J, et al. Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. Psychiatry Res. 2010;178(2):449–50. https://doi.org/10.1016/j.psychres.2009.12.008.CrossRefPubMed

41.

Wiener C, Rassier GT, Kaster MP, Jansen K, Pinheiro RT, Klamt F, et al. Gender-based differences in oxidative stress parameters do not underlie the differences in mood disorders susceptibility between sexes. Eur Psychiatry. 2014;29(1):58–63. https://doi.org/10.1016/j.eurpsy.2013.05.006.CrossRefPubMed

42.

Dadheech G, Sharma P, Gautam S. Oxidative Stress-Induced Response of Some Endogenous Antioxidants in Schizophrenia. Indian J Clin Biochem. 2012;27(3):278–83. https://doi.org/10.1007/s12291-012-0193-z.CrossRefPubMedPubMedCentral

43.

Godin O, Leboyer M, Gaman A, Aouizerate B, Berna F, Brunel L, et al. Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort. Schizophr Res. 2015;168(1–2):388–94. https://doi.org/10.1016/j.schres.2015.07.047.CrossRefPubMed

44.

Chiu CC, Chen CH, Huang MC, Chen PY, Tsai CJ, Lu ML. The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2012;32(5):585–92. https://doi.org/10.1097/JCP.0b013e3182664e64.CrossRefPubMed

45.

Siciliano G, Piazza S, Carlesi C, Del Corona A, Franzini M, Pompella A, et al. Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. J Neurol. 2007;254(5):575–80. https://doi.org/10.1007/s00415-006-0301-1.CrossRefPubMed

Title: Peripheral non-enzymatic antioxidants in patients with schizophrenia: a case-control study
Authors: Zhe Lu
Tianyang Wen
Yingtan Wang
Weijing Kan
Guanglei Xun
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Schizophrenia
Antipsychotics
Antipsychotics
Published in: BMC Psychiatry / Issue 1/2020
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-020-02635-8

2024 ASCO Annual Meeting

Springer Medicine

Peripheral non-enzymatic antioxidants in patients with schizophrenia: a case-control study

Abstract

Background

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Reactive attachment disorder symptoms and prosocial behavior in middle childhood: the role of Secure Base Script knowledge

The influence of depressive symptoms on the effectiveness of a short-term group form of Schema Cognitive Behavioural Therapy for personality disorders: a naturalistic study

Development of ‘learn to dare!’: An online assessment and intervention platform for anxious children

How do worry and clinical status impact working memory performance? An experimental investigation

The biological classification of mental disorders (BeCOME) study: a protocol for an observational deep-phenotyping study for the identification of biological subtypes

Association between depression and healthcare expenditures among elderly cancer patients